



(19) **United States**

(12) **Patent Application Publication** (10) **Pub. No.: US 2003/0124615 A1**

Ens (43) **Pub. Date: Jul. 3, 2003**

(54) **THROMBOXANE B2 METABOLITE AND METHODS FOR REGULATING ASPIRIN-RELATED PLATELET ACTION**

(52) **U.S. Cl.** 435/7.1; 436/71; 514/165

(75) **Inventor: Gordon E. Ens, Denver, CO (US)**

(57) **ABSTRACT**

Correspondence Address:
Katherine M. Kowalchuk
MERCHANT & GOULD P.C.
P.O. Box 2903
Minneapolis, MN 55402-0903 (US)

Disclosed are unique methods for identifying the lowest, yet optimal, aspirin doses for patients. These methods are also characterized as having little to no aspirin-related side-effects. These methods may be used pre-as well as post-thrombotic event, and employs a patient's urinary thromboxane B₂ metabolic levels (e.g., 11-dehydrothromboxane B₂), to identify the patient's platelet activation level. A patient's urinary thromboxane B₂ metabolic level is then used to calculate and appropriate and individualized treatment effective for utilizing platelet activation. Kits for utilizing this technique are also provided. In yet another particular aspect, the invention provides a method for utilizing a random urine sample obtained from a patient to determine whether a patient or particular individual's current dosage of aspirin is providing an adequate and appropriate level of inhibition of platelet activation levels, as compared to inhibition levels observed in individuals not taking aspirin. Also provided are methods that include use of neutraceuticals in combination with the aspirin dosing regimen of the invention. The present invention further includes calibrant preparations. In some embodiments, these calibrants comprise urine, particularly human urine that is identified in repeated trials to provide a consistent and reproducible level of thromboxane B₂ metabolite. As such, they function as control preparations that reduce error from intra-assay sampling measurements.

(73) **Assignee: ESOTERIX, INC. COAGULATION, Aurora, CO (US)**

(21) **Appl. No.: 10/157,431**

(22) **Filed: May 28, 2002**

Related U.S. Application Data

(63) Continuation of application No. 09/697,200, filed on Oct. 26, 2000, which is a continuation-in-part of application No. 09/619,211, filed on Jul. 19, 2000, now abandoned.

(60) Provisional application No. 60/161,462, filed on Oct. 25, 1999.

Publication Classification

(51) **Int. Cl.⁷** **G01N 33/53; G01N 33/92; A61K 31/60**




Figure 1




Figure 2




Figure 3




Figure 4




Figure 5




Figure 6

Figure 7 PURR for baseline and post-81 mg aspirin

Baseline mean : 1669 | Post-81 mg aspirin mean: 537 | Percent inhibition: 68% | p = 0.00000419





Figure 8 : PURR for baseline and post-325 mg aspirin

Baseline mean : 1669 | Post-325 mg aspirin mean: 440 | Percent inhibition: 74% | p = 0.000000192



Donors After May 22




Figure 9

Comparison of Baseline and Post-ASA




Figure 10

**THROMBOXANE B2 METABOLITE AND
METHODS FOR REGULATING
ASPIRIN-RELATED PLATELET ACTION**

RELATED APPLICATION

[0001] The present application is a utility application filing of U.S. Provisional patent application 60/161,462 filed Oct. 25, 1999, to which priority is claimed, and also to U.S. Ser. No. 09/619,211, filed Jul. 17, 2000.

BACKGROUND OF THE INVENTION

[0002] Aspirin (acetyl salicylic acid) effectively reduces the risk of secondary thrombotic events in individuals who have experienced angina, myocardial infarct, peripheral artery disease, or cerebrovascular ischemia. Aspirin also may reduce the risk of initial thrombotic events in healthy individuals. For this reason, many individuals, through physician prescriptions or self-medication, take aspirin on a regular basis for the primary or secondary prevention of thrombotic disease.

[0003] Some important questions remain unanswered. What long-term dosage of aspirin is likely to confer protection from thrombosis while avoiding gastric discomfort or hemorrhagic conditions? What individuals are "resistant" to aspirin, how may aspirin resistance be identified, and what effect does aspirin resistance have on the interpretation of clinical trials?

[0004] Several studies suggest that aspirin, at doses between 30 and 325 mg/day, is effective in reducing the incidence of arterial thrombotic events. Physicians customarily prescribe aspirin to prevent myocardial infarction, cerebrovascular thrombotic disease, and vascular death in individuals with stable angina (1), unstable angina (2), myocardial infarction (3), transient cerebral ischemia, peripheral vascular disease, and thrombotic stroke. (4) For patients with prior acute myocardial infarction or stroke, aspirin prevents up to 40 new thrombotic events per thousand treated. (5) Two large randomized trials demonstrate the thrombosis-reducing efficacy of aspirin for patients with acute ischemic stroke, and aspirin is now routinely prescribed in these conditions. (6,7)

[0005] Aspirin has been shown to be effective in prevention of heart disease in men with several high risk clinical conditions and both men and women with hypertension. (8,9) The Program on the Surgical Control of the Hyperlipidemias categorized a number of individuals who had a partial ileal bypass surgery as smokers and non-smokers and assigned them to aspirin and non-aspirin arms. Within this population, the overall mortality rate was 45.2% for smokers with no aspirin use and only 10.4% for those who reported even infrequent aspirin use. (10)

[0006] Primary Prophylaxis with Aspirin

[0007] Aspirin reduces the incidence of thromboembolic arterial disease in healthy individuals over 50 years of age. (11, 12, 13) In health men, aspirin appears to prevent an average of four thrombotic events per thousand subjects treated. In the Physicians' Health Study, healthy men who took 325 mg of aspirin every other day experienced a mean reduction in the incidence of first myocardial infarction of 44.8% compared to those taking placebos. (14) There was a particularly marked reduction of 59.3% for the morning

peak of infarction, between 4 and 10 a.m. These findings were not confirmed in the British Doctors' study, however, and additional confirmatory studies are in progress, including the current Women's Health Study. (15)

[0008] Aspirin Dosage and Complication

[0009] Hemorrhage and Gastrointestinal Toxicity

[0010] There is a dose-related risk of gastrointestinal bleeding in aspirin therapy, especially in patients who have coagulopathy or who are taking additional anticoagulant therapy such as heparin or warfarin. (16) This is of particular concern in individuals with stomach lesions such as the ulcers associated with *Helicobacter pylori* infection. To avoid hemorrhage, many physicians recommend enteric-coated aspirin, especially if the recommended dosage exceeds 325 mg/day. (17) In the British Doctors' Study, where the prescribed randomized dose was 500 mg/day, 20% of aspirin arm participants dropped out due to dyspepsia or constipation, 3.6% experienced bleeding or bruising, and 2.2% had gastrointestinal blood loss. (18)

[0011] In the Cardiovascular Health Study, Kronmal, et al found a 1.6x relative risk of ischemic stroke and a 4x relative risk for hemorrhagic stroke for healthy women 65 and older who took aspirin. (19) This study presents self-reported, not randomly assigned, aspirin users and illustrates the hemorrhagic risk of high-dose aspirin in particular disease situations.

[0012] For patients who have an elevated risk of thrombosis, the absolute benefit of aspirin prophylaxis clearly outweighs the relatively small risk of bleeding. However, in the individuals with no risk factors, aspirin dosages must be carefully monitored to avoid gastric discomfort, gastric hemorrhage, systemic hemorrhage and hemorrhagic stroke.

[0013] Recommendations for Therapeutic Aspirin Usage

[0014] Because of the preponderance of evidence favoring the protective effects of aspirin against arterial thrombosis, millions rely on aspirin prophylaxis daily either by physician's prescription or self-medication. In a review of clinical studies undertaken in the 1980s and 1990s, Hirsh, Dalen, Fuster, et al make the following recommendations: (4)

[0015] Aspirin is indicated for patients with stable angina, unstable angina, acute myocardial infarction, transient cerebral ischemia, thrombotic stroke, and peripheral arterial disease.

[0016] A dose of 75 to 100 mg/day should be used chronically for all indications, although an initial dose of 160 to 325 mg should be used in acute settings.

[0017] For patients with cerebrovascular disease, a dose of 75 mg/day is effective.

[0018] Aspirin at 100 mg/day is indicated for patients with prosthetic heart valves who develop systemic embolism while on warfarin.

[0019] Aspirin is indicated for patients with atrial fibrillation in whom warfarin is contraindicated.

[0020] There is no recommendation either for or against aspirin usage in normal, healthy adults, and no standards have been established for laboratory monitoring of aspirin's

efficacy, a growing concern a clinicians became aware of aspirin resistance and interindividual pharmacokinetic variations.

[0021] Recent clinical investigations indicate that approximately 10% to 15% of patients on aspirin therapy for prevention of thrombosis have a less than adequate platelet suppression response. (20) Additionally, it is reported that some individuals develop an increasing resistance over time. (21) It is uncertain if this observed resistance is the result of poor absorption, changes in pharmacodynamics, non-compliance, or mechanisms not currently identified. Ridker, et al reported that the positive effect of aspirin appears to be altered by underlying inflammation and further suggested that markers of inflammation such as C-reactive protein may delineate those individuals who will respond atypically to aspirin. (22)

[0022] Platelet Activity Studies and Variable Aspirin Response

[0023] Current laboratory measures of platelet activation include the Mielke template bleeding time, aggregometry, lumiaggregometry, the Date-Behring PFA-100 platelet function analyzer, and the platelet reactivity test. (23) While the platelet-suppressing property of aspirin clearly affects the results of these procedures in general, individuals' laboratory responses to aspirin therapy are idiosyncratic. Trip et al. report 46% of patients with positive spontaneous platelet aggregation results suffered a repeat myocardial infarction. (24) This was the first study that paired clinical outcomes with laboratory results. Helgason, et al demonstrated that seven of 17 patients with atrial fibrillation achieved only partial inhibition of platelet aggregation when taking 325 mg of enteric coated aspirin per day. Non-compliance had no statistical effect on this study's outcome. Helgason's group further demonstrated that 8.2% of patients with previous ischemic stroke exhibited restoration of platelet aggregation (aspirin resistance) despite escalation of aspirin dosage to, ultimately, 1300 mg/day. (25)

[0024] Pappas, et al used a specially designed visual platelet aggregate inspection technique to measure the response to the inhibitory effects of aspirin in 31 healthy young adults. (26) They demonstrated a wide inter-individual variation in response to aspirin that was consistent over 28 days of aspirin ingestion. Mueller, et al performed corrected whole blood aggregometry on patients with intermittent claudication who were taking 100 mg aspirin/day after elective peripheral balloon angioplasty. (27) At any given time, only 40% of males showed complete inhibition of aggregation. Significantly, non-responsive aggregometry results in this study predicted increased risk of reocclusion, leading to the conclusion that aspirin may fail to protect partial- and non-responders from occlusive events.

[0025] Grottemeyer, et al performed whole platelet reactivity tests on 180 internal carotid artery stroke victims given 500 mg of aspirin three times per day. (28) All began with elevated platelet reactivity immediately following stroke. Upon initial aspirin administration, 90% of the subjects demonstrated an immediate suppression of platelet reactivity. However, 60 patients' platelets resumed enhanced platelet reactivity only twelve hours after the initial aspirin dosage. These were termed secondary aspirin non-responders. Over a 24-month period following discharge, 24 (40%) of the secondary aspirin non-responders experienced myo-

cardial infarct, repeat stroke, or vascular death $p < 0.0001$. Of 114 remaining subjects (six were lost to follow-up), only five (4.4%) suffered these major endpoints. Grottemeyer concluded that early identification of secondary aspirin non-responders is an important step to effective prevention of further thrombotic events in post-stroke patients. In an extensive review of aspirin and platelet laboratory studies, Patrono, et al, comments that 10% to 15% of individuals have a poor initial response or demonstrate progressive resistance to aspirin. No large clinical trials have incorporated laboratory measures of platelet activation, so the effect of aspirin resistance on clinical outcomes is currently unknown.

[0026] Komiya, et al used platelet aggregometry to detect cases of aspirin therapy non-compliance and incorrect dosage. They found that 10% of 159 outpatients' results were outside the diagnostic parameters because of non-compliance and that an additional 2% were confirmed compliant but still had normal aggregometry results. (29) Their study illustrates the necessity for monitoring aspirin therapy in patients who may be suspected of non-compliance.

[0027] Aspirin Suppresses Platelet Activity

[0028] Agonists Trigger Platelet Activation

[0029] The cyclooxygenase (COX) biochemical activation pathway, as diagrammed in FIG. 1. This event is essential to normal platelet activation and to the prevention of systemic hemorrhage. (30) COX is also an important activation enzyme in other cells.

[0030] Activation begins when a platelet agonists such as ADP, epinephrine, collagen, or thrombin binds to its platelet membrane receptor site. This activates phospholipase A_2 frees arachidonic acid, a 20-carbon unsaturated fatty acid, from its supporting membranes phospholipid. Free arachidonic acid is a substrate for the COX pathway. (31)

[0031] The Platelet Cyclooxygenase Pathway

[0032] COX, a membrane-associated endoperoxide synthase with two catalytic sites, rapidly modifies the free arachidonic acid in a two-step process. (32) The first catalytic site converts it to the endoperoxide PGG_2 . The Second site, a peroxidase-type site, converts the short-lived PGG_2 to PGH_2 . PGH_2 is then converted by the isomerase action of thromboxane synthase to thromboxane A_2 (TXA_2), which activates the platelet.

[0033] TXA_2 is rapidly hydrolyzed to thromboxane B_2 (TXB_2), a stable plasma product of the COX pathway. TXB_2 , in turn, is converted to a variety of end products, most of which are excreted via the kidney. (33)

[0034] Aspirin Irreversibly Acetylates Cyclooxygenase

[0035] Platelets (and other cells) are now known to produce two isoforms of COX-1 and COX-2. (34) COX-1 is a constitutive membrane-bound enzyme that functions in all normal platelets, whereas COX-2 is a cytokine-inducible enzyme that appears in newly produced platelets and in other cells during inflammation.

[0036] Aspirin irreversible acetylates both COX-1 and COX-2 at serine 529, see FIG. 2. For the COX-1 enzyme, the attached acetyl group sterically hinders arachidonic acid's access to its reactive site. Acetylation does not appear to hinder the activity of COX-2. The inflammation-induced

activity of COX-2 in platelets may account for some cases of aspirin resistance (35), as may pharmacokinetic variations among individuals.

[0037] Aspirin Pharmacokinetics

[0038] Aspirin is rapidly absorbed from the stomach and duodenum and is rapidly hydrolyzed to salicylic acid by esterases in the gut, liver, and erythrocytes. Because only aspirin, not salicylic acid, acetylates COX-1 (or COX-2), a significant proportion of acetylation occurs in the presystemic circulation of the gut and liver. (36). Salicylic acid circulates bound to plasma proteins for up to six hours and is cleared by the kidney.

[0039] Platelets acetylated during the time of peak aspirin levels lose most of their ability to be activated; as reflected in prolonged bleeding times, reduced aggregometry responses, and diminished TXB₂ production. A single dose of 325 mg aspirin is detectable within minutes using these laboratory assays and the effects remain for six to ten days. Platelets with acetylated COX-1 survive normally and continue to participate in the adhesion reaction. Normal platelet function test results are restored only when a predominant population of new platelets has been released from the bone marrow.

[0040] Additional Platelet Activity-Suppressing Substances

[0041] Other non-steroidal anti-inflammatory drugs (NSAIDs) such as dipyridamole, sulphinpyrazone, and ibuprofen act upon COX-1 or other platelet enzymes, but no clinical trials have established antithrombotic properties for these drugs. Ticlopidine, clopidogril, and abiximab exert their antiplatelet activity on membrane receptors. The effects of all these therapeutics may be measured using aggregometry, lumiaggregometry, and plasma, serum, or urine TXB₂ assays.

[0042] In addition, many dietary components and supplements have been shown to modify platelet function by unknown mechanisms. These include fish oil (37), vitamin E (38), garlic (39), red wine, and purple grape juice (40). Herbal and dietary supplements may both interfere with or enhance the effect of aspirin on platelets.

[0043] Janssen, et al provided healthy volunteers with 3 mg of aspirin per day, a study designed to mimic acetylsalicylic acid levels in certain plants. (41). They showed that serum TXB₂ levels were reduced by 39% compared to placebo.

[0044] A number of prospective randomized clinical trials have demonstrated that 50 to 500 milligrams of aspirin per day effectively reduces the risk of primary or secondary arterial thrombotic events in many individuals. Recognition of aspirin's antithrombotic properties has promoted clinical researchers to focus substantial efforts towards modifying platelet function with not only aspirin but a variety of newly developed platelet-suppressive drugs.

[0045] Despite the availability of these new drugs, the use of aspirin for arterial thrombosis prevention continues to increase as public awareness grows. More than 80 billion aspirin tablets are consumed annually in the USA, and more than 37% of the individuals taking aspirin do so to "prevent blood clots". Additionally, individuals who employ alternative medicine practices may consume significant quantities

of red wine, purple grape juice, fish oil, vitamin E, garlic, ginkgo biloba, and other substances known to interfere with platelet function.

[0046] Numerous reports in the scientific literature detail varied individual responses to aspirin dosages. However, little is reported regarding the potential need to adjust aspirin dosage according to individual biologic response or to a changing response over time. Limited studies correlate the occurrence of thrombotic events with individuals who become "resistant" to aspirin.

Subject	3	8	12	14	17	18	24
% Inhibition (81)	60	78	46	48	70	17	10
% Inhibition (325)	44	40	82	83	46	83	38

[0047] Why hasn't aspirin, the drug most widely consumed to modify platelet function, been dosed according to biologic response, in a manner similar to anticoagulants? Because most laboratory tests used to monitor platelet function are time consuming, require expensive equipment (platelet aggregometer), or are traumatic to the patient (bleeding time). In addition, all current assay methods are subject to wide variation in results due to preanalytical and analytical variables, inherent in all ex vivo tests that require the patient's platelets.

SUMMARY OF THE INVENTION

[0048] The present invention, in a general and overall sense, provides a method for identifying an optimal minimal aspirin dose for a patient that is specifically tailored to the patient's specific platelet response levels (i.e., to monitor platelet inactivation).

[0049] The method includes measurement of thromboxane B₂ metabolite levels in the patient to determine the optimum dose for platelet inhibition, with minimum aspirin related side-effects. It is envisioned that the invention, in one aspect, may also be provided in a test kit form. In some embodiments, the kit will be provided together with a solid substrate that is at least partially coated with a material such as an antibody, that is capable of reacting with a thromboxane B₂ metabolite, such as 11-dehydro TXB₂. Also included would be a reactor fluid, such as one that would change in color upon exposure to the thromboxane B₂ metabolite.

BRIEF DESCRIPTION OF THE DRAWINGS

[0050] FIG. 1—Biochemical pathway in a cell showing release of 11-dehydro thromboxane B₂ from thromboxanes B_s.

[0051] FIG. 2—Biochemical pathway showing the reaction products, salicylic acid and acetylated cyclooxygenase from cyclooxygenase and acetylsalicylic acid.

[0052] FIG. 3—dehydro TXB₂/mg creatinine (x axis) vs. frequency (y axis).

[0053] FIG. 4—Comparison of baseline and post-81 mg aspirin and for baseline and post-81 mg ASA. pg. 11-dehydro TXB₂/mg creatinine (x axis) vs. donor numbers (y axis).

[0054] □=Baseline

[0055] ■=Post 81 mg

[0056] **FIG. 5**—Comparison of baseline and post-81 mg aspirin and for baseline and post-325 mg ASA-pg. 11-dehydro TXB₂/mg creatinine (x axis) vs. donor numbers (y axis).

[0057] □=Baseline

[0058] ■=Post 325 mg

[0059] **FIG. 6**—pg TXB₂/mg creatine (x axis) vs. Subjects (y axis)

[0060] □=Baseline

[0061] ■=Post 81 mg

[0062] (Shaded Box) □=Post 325 mg

[0063] **FIG. 7**—Comparison of baseline and post-81 mg aspirin and for baseline and post-81 mg ASA

[0064] **FIG. 8**—Comparison of baseline and post-325 mg aspirin and for baseline and post-325 mg ASA

[0065] **FIG. 9**—Frequency distribution of non-aspirin and aspirin subjects demonstrating the decision point of 400 PURR units—Histogram Comparison of Aspirin and Non-Aspirin Donors. **FIG. 9** is a histogram that illustrates the separation between the non-aspirin and aspirin population.

[0066] **FIG. 10**—Subjects with a <50% response to aspirin in pg/mg and percent inhibition—Histogram Comparison of Aspirin and Non-Aspirin Donors. **FIG. 10** illustrates results from seven subjects whose response to 81 or 325 mg aspirin was “weak” (less than 50%). Note that subjects 12, 14, 18, and 24 responded better to 325 mg, while subjects 3, 8, and 17 responded better to 81 mg, illustrating the idiosyncratic nature of aspirin response and possible resistance.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0067] The following examples are included to demonstrate preferred embodiments of the invention. It should be appreciated by those of skill in the art that the techniques disclosed in the examples which follow represent techniques discovered by the inventor to function well in the practice of the invention, and thus can be considered to constitute preferred modes for its practice. However, those of skill in the art should, in light of the present disclosure, appreciate that many changes can be made in the specific embodiments which are disclosed and still obtain a like or similar result without departing from the spirit and scope of the invention.

EXAMPLE 1

Measuring Platelet Activation

Platelet Aggregometry and In Vitro Activation

[0068] One may detect and measure in vitro platelet activation using aggregometry, which detects platelet aggregation; lumiaggregometry, which detects both aggregation and platelet-specific secretions; or platelet-activation instrumentation such as the Date-Behring PFA-100 platelet function analyzer.

[0069] Platelet Activation Metabolites and In Vitro Activation

[0070] Plasma, serum, or urine assays of platelet secretions and arachidonic acid pathway metabolites may be

employed in the detection of in vitro platelet activation. Assays of plasma or serum TXB₂ are used extensively in platelet function research laboratories where specimen management is carefully controlled, but routine clinical measurement is hampered by the in vitro instability of platelets.

[0071] Aspirin Dosage and Measures of Platelet Activity

[0072] Measurement of aspirin-induced platelet suppression has led to some unexpected findings. Using the arachidonic acid metabolite 12-L-5, 8, 10 - heptadecatrienoic acid (12-HHT) as marker, Beving et al measured aspirin's suppression of platelet activity at three dosages, 30, 75 and 150 mg/day. (42) His group demonstrated that, after seven days' treatment, discontinuing the higher dosages triggered a rebound phenomenon. This was reflected in significantly elevated 12-HHT levels persisting for up to six weeks after stopping aspirin therapy. Further, they demonstrated the rebound to be greater in patients whose baseline levels of 12-HHT were elevated. They concluded that the degree of platelet suppression and ultimate rebound effect could be controlled by determining the pre-aspirin platelet activity via 12-HHT level analysis and by adjusting aspirin dosage accordingly. The rebound effect did not occur in the 30 mg/day dosage arm.

[0073] Buerke et al used bleeding times, platelet aggregometry, and serum TXB₂ assays to demonstrate effective aspirin dosages in healthy males. (43). Comparing various dosage combinations, they recommended a loading dose of 300 mg aspirin in combination with 40 mg/day as a maintenance dose to achieve optimum suppression of platelets. Loading dosages of 40 or 100 mg failed to elicit significant changes within two hours of administration.

[0074] The Urinary Activation Marker 11-dehydro thromboxane B₂

[0075] Whole blood or plasma specimens for platelet metabolite assays require special management because the platelets tend to become activated by changes in temperature, exposure to non-biological surfaces, and mild mechanical agitation. Aggregometry assays are qualitative and technology-intensive, and bleeding time tests have poor predictive values. Thus, it is necessary to locate a metabolite formed in vivo from the products of platelet activation (45).

[0076] Hepatocyte 11-hydroxy thromboxane dehydrogenase acts upon plasma TXB₂. (46) The plasma half-life of 11-dehydro TXB₂ is 45 minutes, and plasma levels remain in the nanogram range, as it is rapidly cleared by the kidney. (47) The urine concentration of 11-dehydro TXB₂, however, is plentiful and, as platelets appear to be its only source, proportionally reflects platelet activity within the previous twelve hours. (46) Urine levels of 11-dehydro TXB₂ are frequently elevated in atherosclerosis, the chronic phase following stroke, transient ischemic attack, intracerebral hemorrhage, and atrial fibrillation. (48) Further, 11-dehydro TXB₂ levels are typically decreased in aspirin therapy, even in cases of atherosclerosis, myocardial infarction, and atrial fibrillation.

[0077] Assays for 11-dehydro TXB₂ have intra- and inter-assay CVs of ≤10% and do not cross-react with TXB₂, 2, 3-dimer TXB₂, nor other cyclooxygenase metabolites (49).

EXAMPLE 2

11-dehydro TXB₂ in Randomly Collected Urine
From Aspirin and Non-Aspirin Donors

[0078] Urine 11-dehydro TXB₂ was assayed in random urine specimens to:

[0079] Establish a reference range in non-aspirin users.

[0080] Determine whether aspirin therapy is related to levels below the reference range.

[0081] Detect aspirin resistance in individuals taking aspirin therapy.

[0082] 11-dehydro TXB₂ Reference Range and results in Aspirin Treatment

[0083] Random urine specimens were collected from 65 individuals who had avoided aspirin for at least two weeks and from 45 individuals who were taking 81 or 325 mg/day by prescription. Each specimen was assayed for 11-dehydro-TXB₂. Specimens were assayed at two dilutions using acetylcholinesterase-linked immunoassay. The results were tested for parallelism and averaged. Urine creatinine was assayed using the Jaffe picrate reaction. To normalize for urinary output, results were expressed in pg 11-dehydro TXB₂/mg creatinine. Results of all populations were compared using the student t-test. Within-day variation is 30% and day-to-day variation 20%.

[0084] A decision point of 100 pg 11-dehydro-TXB₂/mg creatine yields both false negative and false positive rates of 10%, the best achievable combination, as shown in Table 1. Aspirin effect is ruled in at a decision point of 800 pg/mg or less and ruled out of 1000 pg/mg. FIG. 3 is a histogram that illustrates the clear separation between the non-aspirin and aspirin population. Of the aspirin users, six individuals (13%) had results above the decision point and two exceeded the aspirin effect rule-out point of 1000. These six may be aspirin-resistant, and are being observed closely for potential thrombotic events.

TABLE 1

	Decision level in pg/mg	False Positive rate for aspirin effect	True Positive Rate for Aspirin effect	True Positive Rate for aspirin effect	False Negative rate for aspirin effect
Aspirin rule-in	600	0.0%	75.6%	100.0%	24.4%
	700	0.0%	80.5%	100.0%	19.5%
≤800 pg/mg	800	0.0%	80.5%	100.0%	19.5%
	900	1.8%	85.4%	98.2%	14.6%
Recommended	1000	10.5%	90.2%	89.5%	9.8%
	1100	17.5%	90.2%	82.5%	9/8%
Decision point	1200	24.6%	95.1%	75.4%	4.9%
	1300	29.8%	97.6%	70.2%	4.9%
	1400	33.3%	97.6%	66.7%	2.4%
Aspirin rule-out	1500	35.1%	100.0%	64.9%	0.0%
≤1500 pg/mg	1600	42.1%	100.0%	57.9%	0.0%

EXAMPLE 3

Effect of Aspirin on the 11 dehydro TXB₂ Level of Healthy Non-Aspirin Users

[0085] Initiation of aspirin therapy causes mean reduction of 68% for 81 mg/day and 76% for 325 mg/day as illustrated

in FIGS. 4 and 5. There was no significant difference between the 81 mg/day and 325 mg/day suppression levels.

[0086] An immunoassay is provided here that measures the effect of aspirin on platelet function. A stable metabolite of the platelet activation process, 11-dehydro-TXB₂, can be measured in random urine, bypassing the need for ex vivo platelet function. Utilizing this assay, a significant difference individuals taking 81 or 325 mg of aspirin and individuals not taking aspirin was demonstrated. Values equal to or less than 400 pg 11-dehydro-TXB₂/mg creatinine indicates that aspirin in usage is sufficiently inhibiting COX-1 activity. Aspirin users with levels over 500 pg/mg appear to be resistant and not achieving optimal platelet inhibition, as demonstrated in FIG. 3. Utilizing these decision point criteria, 13% of individuals were identified as potential non-responders.

[0087] The present findings demonstrate that the range of non-aspirin results is broad and appears bimodally distributed. The higher peak represents increased platelet activation.

[0088] From the crossover study, seven individuals (30%) had a less than 50% response to either 81 mg or 325 mg of aspirin. Of these, three demonstrated less 11-dehydro TXB₂ excretion at 81 mg than at 325 mg. However, one individual (subject 24) did not demonstrate 50% reduction to 81 mg or 325 mg of aspirin suggesting aspirin resistance. The inhibitory contribution of dietary and lifestyle habits should always be taken into consideration when interpreting data and may have contributed to these results. Further, urine metabolite interference, exercise, and hormonal variation may be responsible for a 20-30% within-day and day-to-day variation.

[0089] Aspirin antithrombotic therapy is long-term therapy. The urine 11-dehydro TXB₂ assay is a readily available means for evaluating individual response to aspirin. It is useful for detecting aspirin resistance and for prescribing and monitoring alternative therapies. The assay is also useful in monitoring patient compliance and determining the lowest aspirin dose that produces effective COX-1 inhibition while avoiding aspirin's unpleasant, sometimes dangerous side effects.

[0090] Using the 11-dehydro TXB₂ assay as the measure of platelet activity, clinical trials will be conducted that 1) further compare biologic response to aspirin's affect on clinical outcomes, 2) evaluate whether dosage adjustment according to COX-1 inhibition will reduce thrombotic events while limiting untoward side effects, and 3) determine whether the influence of inflammatory process, reflected by abnormal C-reactive protein levels, are associated with aspirin resistance.

[0091] Aspirin has been proven to prevent secondary arterial thrombosis in a variety of conditions, and may be used as defined here to prevent primary heart attacks and strokes to those who are at risk. Proper monitoring of aspirin therapy will lead to more accurate dosing, prevention of side effects, and the management of aspirin resistance.

[0092] In a crossover study, 24 healthy individuals who had avoided aspirin for a minimum of 10 days collected random baseline urine specimens. They then took one 81 or 325 mg tablet at 8:00 a.m. and collected a second urine specimen 24 hours after the aspirin was taken. Following a

two-week washout period dosages were reversed and another baseline and 24-hours post-aspirin specimen was collected.

[0093] Results

[0094] Reference Range and Aspirin Values

[0095] Individuals taking 81 to 325 mg/day aspirin exhibit a significantly lower mean PURR than those not taking aspirin (Table 2).

TABLE 2

Comparison of mean PURR units for all aspirin users and non-aspirin users.			
	Aspirin therapy	Aspirin non-users	p-value
N	98	159	
Mean	297	1147	1.5×10^{-19}
SD	330	825	

EXAMPLE 4

[0096] The concept of utilizing 11-dehydrothromboxane measurements to determine individuals in whom aspirin or other platelet modifying compounds is not having a significant platelet inhibiting effect may have several additional applications.

[0097] The antigen antibody assay currently performed by conventional ELISA technique could also be performed using a point of care instrument. The test method would have to be modified such that the reaction could take place and the end point be determined within the confines of the point of care instrument.

[0098] Additionally, it may be possible to adapt the assay for patient self-testing utilizing "dip stick" technology similar to that used for glucose.

EXAMPLE 5

Urinary Thromboxane B₂ Metabolite Monitors the Anti-Platelet Action of Aspirin

[0099] Concern for side effects and laboratory evidence for aspirin "resistance" in up to 20% of individuals make it essential to establish a simple, effective laboratory monitoring system for aspirin's antithrombotic efficacy. The present example demonstrates the utility of the invention for the purpose in human patients.

[0100] 11-dehydrothromboxane B₂ (11-de-H-TXB₂), a stable metabolite of platelet activation was measured in random urine specimens from 65 people who were not taking aspirin and 45 who were taking at least 81 mg/day. The means for non-aspirin users was 2080 pg 11-de-H-TXB₂/mg creatinine, and for aspirin users was 523, p.<0.0000.1. Receiver-operating characteristic analysis yields an optimum decision point of 1000 pg 11-de-H-TXB₂ in random urine may be used to document aspirin's platelet-suppressive effects and to identify individuals who may not achieve antithrombotic benefits.

EXAMPLE 6

Calibrants for Use in Assay of Thromboxane B₂ Metabolite

[0101] It is envisioned that the invention will include a set of calibrating materials that will be used to even better

standardize the methods of the invention. These calibrants are described in the present example. In particular, including 1, 2, 3, 4, 5 or more calibrants as described here, in the assay method will improve the consistency of interassay results over time and under a variety of conditions, and will provide reliable, reproducible, and directly correlateable test results as between different assay patient sample blocks for assessing response to a variety of different doses of aspirin.

[0102] In some embodiments, it is envisioned that there will be prepared a set of five different calibrants. These calibrants will provide a reference point metabolite curve. For example, where the set comprises five calibrants, a ready group of five reliable reference points for identifying TxB₂ levels in unknown patient urine samples may be assessed. The target values of the calibrant will provide better intra assay standardization, considered to be alike to any biological control material. These "calibrant" control preparations were derived by repeatedly assaying, computing the mean, and the action limits at ± 2 SD. Any single run whose controls i.e., calibrants fall outside the two standard deviation limit is invalidated.

[0103] The calibrants of the present invention will also be used to normalize results should systematic error affect assay results. Systematic error may be easily introduced by reagent or instrument changes. Normalizing, i.e. adjusting reported results to a constant, may be accomplished through the application of the calibrants.

[0104] Calibrants are urine specimens from individuals with metabolite results that have provided a consistent reading in the present assay, and are spread across the spectrum of possible results. These specimens are aliquotted and frozen at -70 degrees centigrade for long-term storage. Their values are obtained through performance of 25 repeated assays over at least 25 days with subsequent computation of repeat assay means and standard deviations.

[0105] In creating the calibrants, urines were selected from people whose previously assayed results were available in the inventor's laboratory. By doing this, samples were selected that had optimum levels representing the whole range. No pooling was performed, rather, individual urines were aliquotted and frozen. Establishing a calibrator in this instance is done by assaying the patient urine sample 20 to 25 times over a minimum of 20 days, then computing the mean and action limits using a 95% confidence interval computation. Eleven to twelve data points for each of the five calibrants have now been created. The means will then serve as target values for subsequent test runs.

	Calibrants				
	1. TXB ₂ pg/mL				
	CJ100	GE300	PM500 Dil: 1:2	EB900 Dil: 1:2	SS600 Dil: 1:4
	25628	55278	115812	96970	
	26561	54710	80278	100746	
	24332	53334	104782	92484	
	26931	54614	109228	109228	
	27255	49114	96286		
		40651	97938	87860	

-continued

20623	50941	109758	78924	103140	
				108200	
				104244	
				115944	
22864	54214	118336	87618		
				123520	
				184068	
				102576	
17319	35274	145844	113168	116332	
				67924	
				96904	
20790	46457	99218	78852	107268	
				99372	

Preliminary TXB2 Statistics

N =	9	10	10	9	12
Mean =	23589.2	49458.7	107748.0	93983.3	110791.0
StDev =	3439.13	6796.70	17315.51	12201.98	26862.67
Upper Limit =	30467.5	63052.1	142379.0	118387.3	164516.3
Lower Limit =	16711.0	35865.3	73117.0	69579.4	57065.7
CV % =	14.6	13.7	16.1	13.0	24.2

[0106]

2. Creatinine mg/dL

	CJ100	GE300	PM500	EB900	SS600
	116	155	131	97	
	111	153	139	96	
	107	157	138	102	
	114	161	140	96	
	114	152	133	93	142
	111	149	137	92	135
	119	157	143	100	138
	108	150	134	101	142
	110	118	133	90	134
	101	147	129	87	128
	111	147	137	101	144

Creatinine Statistics

N =	11	11	11	11	7
Mean =	111.1	149.6	135.8	95.9	137.6
StDev =	4.83	11.40	4.19	4.95	5.65
Upper Limit =	120.7	172.4	144.2	105.8	148.9
Lower Limit =	101.4	126.8	127.4	86.0	126.3
CV % =	4.3	7.6	3.1	5.2	4.1

[0107]

3. PURR

	CJ100	GE300	PM500	EB900	SS600
	231	369	853	1011	
	239	366	591	1050	
	219	356	771	964	
	242	365	804	1139	
	245	328	709		
		272	721	916	

-continued

	186	340	808	823	750
					787
					758
					843
	206	362	871	914	
					898
					1338
					746
	156	236	1074	1180	846
					494
					704
	187	310	731	822	780
					722

Preliminary PURR Statistics

N =	9	10	10	9	12
Mean =	212.3	330.5	793.3	979.9	805.3
StDev =	30.96	45.42	127.49	127.22	195.26
Upper Limit =	274.3	421.4	1048.3	1234.4	1195.9
Lower Limit =	150.4	239.7	538.3	725.5	414.8
CV % =	14.6	13.7	16.1	13.0	24.2

[0108] The following designation of calibrants as envisioned by the inventors represents at least one of the embodiments of the invention.

- [0109] Calibrant1—(Low)
- [0110] Calibrant2—(Medium-Low)
- [0111] Calibrant3—(Medium)
- [0112] Calibrant 4—(Medium High)
- [0113] Calibrant 5—(High)

[0114] It is anticipated that calibrants for use in the assessment of aspirin response as part of the present assay will be created from other than human urine, and thus are not limited to human urine calibrants alone.

EXAMPLE 7

Combination Therapies of Aspirin Together with Neutraceuticals

[0115] Aspirin, through its antiplatelet effect, reduces the risk of cardiovascular disease in most high-risk individuals. However, evidence of aspirin resistance in up to 20% of individuals makes it essential to establish a simple, effective laboratory monitoring system for aspirin's antiplatelet activity. The ability to monitor aspirin's antiplatelet effect may be mitigated by the effects of dietary components, and in particular by that group of compounds known as neutraceuticals. By way of example, that group of compositions known to comprise neutraceuticals includes purple grape juice, supplements such as vitamin E, St. Johns Wort, and the like.

[0116] 11-dehydro thromboxane B₂, a stable metabolite of platelet-specific cyclooxygenase activity, in urine specimens from 29 individuals was measured. Participants were instructed to drink controlled daily volumes of purple grape juice, 400 international units per day of vitamin E, and 650 mg per day of aspirin. Each intervention was given in one-week intervals separated by a one-week washout period. The metabolite was measured in baseline, post-intervention, and post-washout urine specimens and the results were

expressed as platelet urinary response ratios (PURR) based upon pg 11-dehydrothromboxane B₂/mg creatinine. Results are shown in the table. Vitamin E has no measurable effect, grape juice has a small but significant effect, and aspirin has a large and statistically significant effect upon urinary excretion of the platelet cyclooxygenase metabolite 11-dehydrothromboxane B₂.

[0117] Other non-steroidal anti-inflammatory drugs (NSAIDs) such as acetaminophen, dipyridamole, sulphinpyrazone, or ibuprofen act upon COX-1 or other platelet enzymes. Ticlopidine, clopidogril, and abciximab exert their antiagometry on plasma, serum, and in urine TXB₂ assays.

[0118] Many dietary components and supplements have been shown to modify platelet function by unknown mechanisms. These include fish oil, vitamin E, garlic, red wine, and purple grape juice. Herbal and dietary supplements may both interfere with or enhance the effect of aspirin on platelets. Therefore, when used in combination with the present invention, the particular patient's aspirin dose response and clinical condition would be considered in deciding to place the patent on a regimen that includes certain neutraceuticals, or that excludes others.

TABLE 3

Weber Donor	Baseline	Post-Grape Juice	First Washout	Second Washout	Mean Baseline
001	1349	1469	774	1355	1159
002	1058	857	936	1211	1069
003	911	1070	1588		1250
004	917	649	913	758	863
005	708		811	754	758
006	1269	664	1600	1106	1325
007	867	585	461	669	666
009	723	796	977	915	872
010	865	830	1083	902	950
011	1578	901	1748	1449	1591
012	1725	1505	1631	2009	1788
014	786	1437	627		707
015	1151	816	956	1046	1051
016		689	801		801
017	989	384	435	756	727
018	608	796	843	743	731
019	744	1387	1490	829	1021
021	828	466	887	843	852
022	965	746	1598		1282
023	1809	654	871		1340
024	1034	463	449	506	663
025	670	833	541	1228	813
026	2168	1763	1847		2007
027	1730	937	945	1345	1340
029	639	948	611	825	692
030	3604	1391	1792		2698
031	874	750			874
033	850	911	1312		1081
034	1071	1290			1071
N	28	28	27	19	29
Mean	1160.3	920.9	1056.6	1013.1	1105
SD	623.1	359.3	448.8	355.1	456.5

[0119] Percent reduction: 16.6

[0120] The reduction of 16.6% post grape-juice is significant at p<0.05 for the one-tail test.

[0121] t-Test: Two-Sample Assuming Equal Variances

[0122] Mean Baseline to Post-Grape Juice

	Variable 1	Variable 2
Mean	1104.827671	920.9479068
Variance	208394.0792	129070.2794
Observations	29	28
Pooled Variance	169453.3048	
Hypothesized Mean Difference	0	
df	55	
t Stat	1.685968679	
P(T <= t) one-tail significant at <0.05	0.048733764	
t Critical one-tail	1.673033694	
P(T <= t) two-tail	0.097467528	
t Critical two-tail	2.004044291	

[0123]

TABLE 4

	Mean Baseline	Mean Post-Grape Juice	Mean Post-Vitamin E	Mean Post-Aspirin
N:	29	28	26	19
PURR:	1105	920.9	1293.1	379.7
% Change:		-16.6%	+14.3%	-65.6%
P:		0.049*	0.113	2.365 × 10 ⁻⁷ *

Significant at P < 0.05

Additional platelet activity-suppressing substances

EXAMPLE 8

Baseline for Positive Aspirin Response

[0124] The present example describes another embodiment of the method by which the response to aspirin may be assessed. It was discovered that by changing the buffer that was used to prepare the test urine sample, the cut-off for identifying a response to the aspirin could be further defined, and reduced to a value of about 400 pg.

[0125] The PURRs generated in the 11-dehydro thromboxane B₂ assay in the present example were higher than those generated in subsequent studies. The average reduction after the investigators initial assay was 60%. This change was a result of a reformulation of the reagent buffer. Reformation of the buffer was made by the supplier, Cayman Chemical Corporation. The initial buffer was thought to be a phosphate saline buffer. The reformatted buffer is an alpha diethanolamine buffer. Cayman Chemical indicates that the antibody used in the test is only reactive with the free acid form of the 11-dehydro thromboxane B₂. The buffer change was made to convert any lactone form present in the same urine to the free acid form of the thromboxane. The current procedure requires a two-hour pre-incubation of the urine sample in the diethanolamine buffer in order to allow for the conversion of the forms before pipetting to the plate. The new decision point for the assay is 400 PURR units, down from the original 1000.

[0126] Neutraceuticals may mimic aspirin's activity and therefore cause aspirin-like results in the assay. Thus, ASPIRINcheck patients may be cautioned to discontinue these for a few days. Neither Vitamin E nor grape juice has had such an effect. More dietary supplements, including garlic, ginko biloba, and St. John's Wort will be made. Perhaps a supplement that closely mimics the anti-platelet

effect of aspirin will be identified. If so, it may be used as an adjunct or alternative to aspirin therapy, and would be considered an additional embodiment of the invention, such as in a combination therapy, and would be considered an additional embodiment of the invention, such as in a combination therapy method.

EXAMPLE 9

Platelet Urinary Response Ratio (PURR)

[0127] To normalize for urinary output, results are expressed as platelet urinary response ratio (PURR) based upon pg 11-dehydro TXB₂/g creatinine. Results of all populations were compared using the student t-test.

[0128] Effect of Aspirin on 11-dehydro TXB₂ in Healthy Non-Aspirin Users

TABLE 5

Comparison of mean PURR units for all aspirin users and non-aspirin users.

	Aspirin therapy	Aspirin non-users	p-value
N	98	159	
Mean	297	1147	1.5 × 10 ¹⁹
S0	330	825	

[0135]

TABLE 6

Determining the decision point by computing and comparing error rates establishes the recommended decision point of 400 PURR Units

All data	Decision level in Platelet Urinary Response Ratio	False positives; non-ASAs in ASA range	True positives; ASAs in ASA range	False negatives; ASAs in non-ASA range	True negatives; non-ASAs in non-ASA range	Total ASAs	Total non-ASAs	False positive % for aspirin effect	True positive % (sensitivity) for aspirin effect	False negative % for aspirin effect	True negative % (specificity) for aspirin effect	Total FP % and FN %
	200	3	50	48	156	98	159	1.9	51.0	49.0	98.1	50.9
	250	5	61	37	154	98	159	3.1	62.2	37.8	96.6	40.9
	300	9	70	28	150	98	159	5.7	71.4	28.6	94.3	34.2
	350	11	77	21	148	98	159	6.9	78.6	21.4	93.1	28.3
Decision Point	400	16	81	17	143	98	159	10.1	82.7	17.3	89.9	27.4
Repeat Analysis	450	22	83	15	137	98	159	13.8	84.7	15.3	86.2	29.1
Repeat Analysis	500	23	85	13	135	98	159	14.5	86.7	13.3	85.5	27.7
	550	30	86	12	129	98	159	18.9	87.8	12.2	81.1	31.1
	600	36	88	10	123	98	159	22.6	89.8	10.2	77.4	32.8

[0129] In a crossover study, twenty-four healthy individuals who had avoided aspirin for a minimum of ten days collected random baseline urine specimens. They then took one 81 or 325 mg tablet at 8:00 AM and collected a second urine specimen 24 hours after the aspirin was taken. Following a 2-week washout period dosages were reversed and another baseline and 24-hours post-aspirin specimen was collected.

[0130] Effect of Aspirin on the PURR of Healthy Non-Aspirin Users

[0131] Initiation of aspirin therapy causes mean reduction of 68% for 81 mg/day and 76% for 325 mg/day as illustrated in FIGS. 7 and 8. There was no significant difference between the 81 mg/day and 325 mg/day suppression levels. Data was generated using a different formulation, this accounts for the higher range of PURR units.

[0132] Results

[0133] Reference Range and Aspirin Values

[0134] Individuals taking 81 to 325 mg/day aspirin exhibit significantly lower levels of 11-dehydro-TXB₂ than those not taking aspirin See Table 5.

[0136] Results

[0137] Individuals taking 81 mg/day to 325 mg/day aspirin exhibit a significantly lower mean PURR than those not taking aspirin.

[0138] All of the compositions and methods disclosed and claimed herein can be made and executed without undue experimentation in light of the present disclosure. While the compositions and methods of this invention have been described in terms of preferred embodiments, it will be apparent to those of skill in the art that variations may be applied to the composition, methods and in the steps or in the sequence of steps of the method described herein without departing from the concept, spirit and scope of the invention. More specifically, it will be apparent that certain agents, which are both chemically and physiologically, related may be substituted for the agents described herein while the same or similar results would be achieved. All such similar substitutes and modifications apparent to those skilled in the art are deemed to be within the spirit, scope and concept of the invention as defined by the appended claims.

REFERENCES

- [0139] The following references, to the extent that they provide exemplary procedural or other details supplementary to those set forth herein, are specifically incorporated herein by reference.
- [0140] 1. Juul-Moler S., Edvardsson N., Jahnmatz B., et al., *Lancet* 1992; 340: 1421.
- [0141] 2. The RISC Group, *Lancet* 1992; 340: 1421.
- [0142] 3. ISIS-2 Collaborative Group; ISIS-2, *Lancet* 1988; 2: 349
- [0143] 4. The Dutch TIA Study Group, *N. Engl. J. Med.* 1991; 325: 1261.
- [0144] 5. Hirsh J., Dalen J. E., Fuster V., Harker L. B., Patrono C., Roth G., *Chest* 1995; 108 Suppl.: 247s.
- [0145] 6. International Stroke Trial Collaborative Group, *Lancet* 1997; 349: 1569.
- [0146] 7. CAST (Chinese Acute Stroke Trial) Collaborative Group, *Lancet* 1997; 349: 1641.
- [0147] 8. The Medical Research Council's General Practice Research Framework, *Lancet* 1998; 351: 233.
- [0148] 9. Hansson L., Zanchetti A., Carruthers S. G., et al., *Lancet* 1998; 351: 1755.
- [0149] 10. Fitch L. L., Buchwald H., Matts J. P., *Am. Heart J.* 1995; 129: 656.
- [0150] 11. Antiplatelet Trialists' Collaboration, *BMJ* 1994; 308: 81.
- [0151] 12. Hennekens C. H., Peto R., Hutchinson G. B., et al., *N. Engl. J. Med.* 1988; 318: 923.
- [0152] 13. Manson J. E., Stampfer M. J., Colditz G. A., et al., *JAMA* 1991; 266: 521.
- [0153] 14. Ridker P. M., Manson J. E., Buring J. E., Muller J. E., Hennekens C. H., *Circulation* 1990; 82: 897.
- [0154] 15. Buring J. E., Hennekens C. H., *J Myocardial Ischemia* 1992; 4: 27.
- [0155] 16. Roderick P. J., Wilkes H. C., Meade T. W., *Br. J. Clin. Pharmacol* 1993; 35: 219.
- [0156] 17. Petroski D., *Lancet* 1997; 349: 430.
- [0157] 18. Petro R., Gray R., Collins R., et al., *BMJ* 1988; 296: 313.
- [0158] 19. Kronmal R. A., Hart R. G., Manolio T. A., *Stroke* 1998; 29: 887.
- [0159] 20. He J., Whelton P. K., Vu B., Klag M. J., *JAMA* 1998; 280: 1930.
- [0160] 21. Patrono C., Collier B., Dalen J., et al., *Chest* 1998; 114 Suppl.: 470s.
- [0161] 22. Helgason C. M., Hoff J. A., Kondos G. T., Brace L. D., *Stroke* 1993; 24: 1458.
- [0162] 23. Ridker P. M., Cushman M., Stampfer M. J., Tracy R. P., Hennekens C. H.
- [0163] 24. Wu K. K., Hoak J. C., *Lancet II*; 1974: 924.
- [0164] 25. Trip M. D., Cats V. M., Van Capelle F. J. L., Vreken J., *New Engl. J. Med.* 1990, 322: 1549.
- [0165] 26. Helgason C. M., Bolin K. M., Hoff J. A., et al., *Stroke* 1994; 25: 2331.
- [0166] 27. Pappas J. M., Westengard J. C., Bull B. S., *Arch. Path. Lab. Med.* 1994; 118: 801.
- [0167] 28. Mueller M. R., Salat A., Stangl P., *Thromb. Haemost* 1997; 78: 1003.
- [0168] 29. Grottemeyer K. H., Scharafinski H. W., Husted I. W., *Thrombos. Res.* 1993; 71: 397.
- [0169] 30. Komiya T., Kudo M., Urabe T., Mizuno Y., *Stroke* 1994; 25: 2337.
- [0170] 31. Israels L. G.
- [0171] 32. Rifkin R. M.,
- [0172] 33. Vane J. R., Botting R. M., *Semin. Arthr. Rheum.* 1997; 25 Suppl. I: 2.
- [0173] 34. Lawson J. A., Patrono C., Ciabattone G., et al., *Anal. Biochem.* 1986, 155: 198.
- [0174] 35. Schror K., *Semin. Thrombos. Hemostas.* 1997; 23: 349.
- [0175] 36. Weber A. A., Zimmernann K. C., Meyer-Kirchraht J., Schror K., *Lancet* 1999; 353: 900.
- [0176] 37. Pedersen A. K., Fitzgerald G. A., *New Engl. J. Med.* 1984; 311: 1206.
- [0177] 38. Schmidt E. B., Dyerberg J., *Drugs* 1994; 47: 405.
- [0178] 39. Weber P., Dendich A., Machlin L. J., *Nutr.* 1997; 13: 450.
- [0179] 40. O'neil C. K., Avila J. R., Fetrow C. W., *Nursing* 1999; 58.
- [0180] 41. Rotondo S., Rotilio D., Cerletti C., De Gaetano G., *Thrombos Haemostas* 1994; 72: 813.
- [0181] 42. Jannsen P. L. T. M. K., Akkerman J.-W. N., Hollman P. C. H., Van Staveren W. A., Zwaginga J.-J., Katan M. B., *Eur. J. Clin. Nutr.* 1995; 49: 365.
- [0182] 43. Beving H., Eksborg S., Malingren R. S., et al., *Thrombos. Res.* 1994; 74: 39.
- [0183] 44. Buerke M., Pittroff W., Meyer J., Darius H., *Am. Heart J* 1995; 130: 465.
- [0184] 45. May J. A., Heptinstall S., Cole A. T., Hawkey C. J., *Thrombos. Res.* 1997; 88: 183.
- [0185] 46. Samuelsson B., Granstrom E., Green K., et al., *Ann. Rev. Biochem.* 1975; 44: 669.
- [0186] 47. Catella F., Fitzgerald G. A., *Thrombos. Res.* 1987; 47: 647.
- [0187] 48. Catella F., Healy D., Lawson J. A., et al., *Proc. Natl. Acad. Sci. USA* 1986; 83: 5861.
- [0188] 49. Van Kooten F., Ciabattone G., Koudstaal P. J., Dippel W. J., Patrono C., *Stroke* 1999; 30:546.
- [0189] 50. Lellouche F., Fradin A., Fitzgerald G., et al., *Prostaglandins* 1990; 40: 297.

What is claimed is:

1. A method for determining a minimum optimum aspirin dose for inhibiting platelet activation in a patient treatment regimen comprising:

measuring a level of thromboxane B₂ metabolite in a patient test sample to provide a baseline thromboxane B₂ metabolite level;

determining a level of platelet activation in a urine sample from the patient from whom the test sample was obtained to provide a baseline platelet activation level;

comparing the level of thromboxane B₂ metabolite in the test sample and the amount of platelet activation in the urine sample;

providing a series of aspirin doses to the patient of 80 mg aspirin, a 200 mg aspirin and of 300 mg aspirin and obtaining a test sample and a urine sample after each dosage; and

identifying the aspirin dosage level that results in a thromboxane B₂ metabolite level of less than about 500 mg thromboxane B₂ metabolite to provide a reference aspirin dosage level end-point, wherein the aspirin dosage level that decreases platelet activation 90% to 95% relative to the baseline platelet activation level is the minimum optimum aspirin dose for inhibiting platelet activation

2. The method of claim 1 wherein the thromboxane B₂ metabolite is 11-dehydrothromboxane B₂.

3. The method of claim 1 wherein the patient treatment regimen is a treatment regimen for a post-thrombotic event patient.

4. The method of claim 1 wherein the patient treatment regimen is a treatment regimen for a patient diagnosed as having had ischemia, intracerebral hemorrhage, arterial fibrillation, cardiac catheterization, lupus, or coronary angioplasty.

5. The method of claim 1 wherein the test sample is a urine sample.

6. The method of claim 1 wherein the test sample is a blood sample.

7. The method of claim 1 wherein the test sample is a plasma sample.

8. The method of claim 1 wherein the aspirin dosage level that results in a thromboxane B₂ metabolite level of less than about 400 mg thromboxane B₂ metabolite provides the reference aspirin level end point.

9. A kit for monitoring blood platelet activation comprising:

a substrate capable of attaching thereto an antibody capable of binding to a thromboxane B₂ metabolite; and

a color-indicator liquid material capable of reacting with an antibody that binds to a thromboxane B₂ metabolite.

10. The kit of claim 8 further defined as comprising an instruction sheet.

11. A calibrant for use in assessing patient response to aspirin comprising urine that provides a consistent level of thromboxane B₂ metabolite.

12. The calibrant of claim 11 further defined as comprising human urine.

13. The calibrant of claim 12 wherein the thromboxane B₂ metabolite is further defined as 11-dehydrothromboxane B₂.

14. The calibrant of claim 11 further defined as a control value in assessing patient response to aspirin

15. An assay kit for assessing dose response to aspirin comprising:

the calibrant of claim 11;

a substrate capable of attaching thereto an antibody capable of binding to a Thromboxane B₂ metabolite; and

a color-indicator liquid material capable of reacting with an antibody that binds to a thromboxane B₂ metabolite.

16. The assay kit of claim 15 wherein the thromboxane B₂ metabolite is further defined as 11-dehydrothromboxane B₂.

17. The assay kit of claim 15 further defined as comprising a set of human urine calibrants.

18. A set of calibrant preparations as defined in claim 11, wherein each calibrant of said set provides a reproducible measurable level of a thromboxane B₂ metabolite

19. The set of calibrant preparations of claim 18 further defined as comprising three calibrant preparations.

20. The set of calibrant preparations of claim 18 or 19 further defined as comprising human urine.

* * * * *

专利名称(译)	血栓素B2代谢物和调节阿司匹林相关血小板作用的方法		
公开(公告)号	US20030124615A1	公开(公告)日	2003-07-03
申请号	US10/157431	申请日	2002-05-28
[标]申请(专利权)人(译)	ESOTERIX 混凝		
申请(专利权)人(译)	ESOTERIX, INC. 混凝		
当前申请(专利权)人(译)	ESOTERIX, INC. 混凝		
[标]发明人	ENS GORDON E		
发明人	ENS, GORDON E.		
IPC分类号	C07B63/00 C10G19/00 C10L3/10 G01N33/86 G01N33/88 G01N33/53 G01N33/92 A61K31/60		
CPC分类号	C07B63/00 C10G19/00 Y10S435/975 G01N33/86 G01N33/88 C10L3/10		
优先权	60/161462 1999-10-25 US		
其他公开文献	US6994983		
外部链接	Espacenet USPTO		

摘要(译)

公开了用于鉴定患者的最低但最佳的阿司匹林剂量的独特方法。这些方法的特征还在于几乎没有阿司匹林相关的副作用。这些方法可以在血栓前事件之前以及血栓形成后事件中使用，并且使用患者的尿血栓素B2代谢水平（例如，11-脱氢血栓素B2）来识别患者的血小板活化水平。然后使用患者的尿血栓素B2代谢水平来计算和有效利用血小板活化的适当和个体化治疗。还提供了用于利用该技术的试剂盒。在另一个特定方面，本发明提供了一种利用从a获得的随机尿液样品的方法患者确定患者或特定个体当前的阿司匹林剂量是否提供了足够和适当水平的血小板活化水平抑制，与未服用阿司匹林的个体中观察到的抑制水平相比较。还提供了包括将营养保健品与本发明的阿司匹林给药方案组合使用的方法。本发明还包括校准物制剂。在一些实施方案中，这些校准物包含尿液，特别是人尿液，其在重复试验中鉴定，以提供一致且可再现水平的血栓素B2代谢物。因此，它们起到控制制剂的作用，从而减少测定内取样的误差测量。




Figure 1